赛诺菲宣布16亿美元收购！

生物制品圈07-26

近期，制药企业在呼吸道疫苗市场动作频频。赛诺菲公司日前宣布，将以高达 16 亿美元的价格收购英国生物技术公司 Vicebio Ltd. 。根据协议，赛诺菲将预先支付 11.5 亿美元，后续若某些关键节点达成协议，还将支付高达 4.5 亿美元的额外款项。通过此次收购，赛诺菲不仅获得了 Vicebio 处于探索性临床试验阶段、针对呼吸道合胞病毒(RSV)和人类偏肺病毒(hMPV)的单一疫苗，还有望借助...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2554171521?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-26 15:33","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2554171521","market":"us","top_or_hot":-1,"title":"赛诺菲宣布16亿美元收购！","media":"生物制品圈","content":"<div>\n<p>近期，制药企业在呼吸道疫苗市场动作频频。赛诺菲公司日前宣布，将以高达 16 亿美元的价格收购英国生物技术公司 Vicebio Ltd. 。根据协议，赛诺菲将预先支付 11.5 亿美元，后续若某些关键节点达成协议，还将支付高达 4.5 亿美元的额外款项。通过此次收购，赛诺菲不仅获得了 Vicebio 处于探索性临床试验阶段、针对呼吸道合胞病毒(RSV)和人类偏肺病毒(hMPV)的单一疫苗，还有望借助...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726154144a4647176&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>赛诺菲宣布16亿美元收购！</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n赛诺菲宣布16亿美元收购！\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-26 15:33 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726154144a4647176&s=b><strong>生物制品圈</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>近期，制药企业在呼吸道疫苗市场动作频频。赛诺菲公司日前宣布，将以高达 16 亿美元的价格收购英国生物技术公司 Vicebio Ltd. 。根据协议，赛诺菲将预先支付 11.5 亿美元，后续若某些关键节点达成协议，还将支付高达 4.5 亿美元的额外款项。通过此次收购，赛诺菲不仅获得了 Vicebio 处于探索性临床试验阶段、针对呼吸道合胞病毒(RSV)和人类偏肺病毒(hMPV)的单一疫苗，还有望借助...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726154144a4647176&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SG9999011175.SGD","symbol_name":"Nikko AM Global Dividend Equity Dis SGD-H","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726154144a4647176&s=b","article_id":"2554171521","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250726154144a4647176&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2554171521","pubTimestamp":1753515229,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"赛诺菲公司日前宣布，将以高达 16 亿美元的价格收购英国生物技术公司 Vicebio Ltd. 。根据协议，赛诺菲将预先支付 11.5 亿美元，后续若某些关键节点达成协议，还将支付高达 4.5 亿美元的额外款项。此次收购进一步巩固了赛诺菲在呼吸道病毒疫苗市场的布局，推动其更接近研发出新一代能在一次注射中为人体提供对多种呼吸道病毒防护的疫苗。此外，今年 2 月，阿斯利康曾以 11 亿美元收购了 Icosavax 。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"SG9999011175.SGD":"Nikko AM Global Dividend Equity Dis SGD-H","BK4585":"ETF&股票定投概念","LU0306807586.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" (USD) INC QF","SG9999013999.USD":"UOB UNITED GLOBAL HEALTHCARE FUND (USDHDG) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU0321505439.SGD":"Schroder ISF Global Dividend Maximiser A Acc SGD","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","VLP":"Valero Energy Partners LP","LU0321505868.SGD":"Schroder ISF Global Dividend Maximiser A Dis SGD","BK4139":"生物科技","LU0234572021.USD":"高盛美国核心股票组合Acc","IE0002270589.USD":"LEGG MASON CLEARBRIDGE VALUE \"A\" (USD) INC","SG9999001176.SGD":"UOB UNITED GLOBAL HEALTHCARE \"SGD\" (ACC)","BK4533":"AQR资本管理(全球第二大对冲基金)","LU0985481810.HKD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (HKD) INC M","ICVX":"Icosavax, Inc.","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU0225284248.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" ACC","LU0456855351.SGD":"JPMorgan Funds - Global Equity A (acc) SGD","LU0058720904.USD":"联博国际健康护理基金A","LU1894683264.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) ACC","BK4592":"伊斯兰概念","SG9999001176.USD":"United Global Healthcare Acc USD","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU1894683348.USD":"AMUNDI FUNDS US EQUITY RESEARCH VALUE \"A2\" (USD) INC","LU1066051498.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (USD) INC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","BK4568":"美国抗疫概念","IE00BLSP4452.SGD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis SGD-H Plus","BK4550":"红杉资本持仓","BK4588":"碎股","SG9999003800.SGD":"Nikko AM Global Dividend Equity Acc SGD-H","SG9999002232.USD":"Allianz Global High Payout USD","BK4007":"制药","LU0170899867.USD":"EASTSPRING INVESTMENTS WORLD VALUE EQUITY  \"A\" (USD) ACC","LU0306806265.USD":"SCHRODER ISF GLOBAL DIVIDEND MAXIMISER \"A\" ACC","SG9999002224.SGD":"Allianz Global High Payout SGD","LU1883839398.USD":"AMUNDI FUNDS INCOME OPPORTUNITIES \"A2\" (USD) ACC","LU0225771236.USD":"SCHRODER ISF GLOBAL EQUITY YIELD \"A\" (USD) INC MF","IE00B19Z3581.USD":"Legg Mason ClearBridge - Value A Acc USD","BK4539":"次新股","LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4534":"瑞士信贷持仓","BK4581":"高盛持仓","BK4599":"减肥药","IE00B19Z3B42.SGD":"Legg Mason ClearBridge - Value A Acc SGD"},"translate_title":"Sanofi announces $1.6 billion acquisition!","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VLP":1,"ICVX":0.84},"content_text":"近期，制药企业在呼吸道疫苗市场动作频频。赛诺菲公司日前宣布，将以高达 16 亿美元的价格收购英国生物技术公司 Vicebio Ltd. 。根据协议，赛诺菲将预先支付 11.5 亿美元，后续若某些关键节点达成协议，还将支付高达 4.5 亿美元的额外款项。通过此次收购，赛诺菲不仅获得了 Vicebio 处于探索性临床试验阶段、针对呼吸道合胞病毒(RSV)和人类偏肺病毒(hMPV)的单一疫苗，还有望借助其 “分子钳” 技术，加速开发出完全以液体形式存在的联合疫苗。该技术能稳定病毒糖蛋白的天然形状，增强人体对糖蛋白的免疫反应，简化疫苗生产流程和配送环节，无需冷冻或冻干，降低生产成本和难度。这一技术还具有 “即插即用” 的优势，可用于不同病毒疫苗的研发，无需在生产场所进行大规模投资。此次收购进一步巩固了赛诺菲在呼吸道病毒疫苗市场的布局，推动其更接近研发出新一代能在一次注射中为人体提供对多种呼吸道病毒防护的疫苗。据悉，Vicebio当前的重要管线是VXB-241，这是一款针对RSV+hMPV的双价疫苗，正在进行I期临床。早期数据显示，该疫苗在60岁以上人群中表现出良好耐受性。此外，今年 2 月，阿斯利康曾以 11 亿美元收购了 Icosavax 。Icosavax 是一家专注于利用创新病毒样颗粒(VLP)平台开发差异化、高潜力疫苗的生物科技公司。其主打项目 IVX - A12 是一种针对呼吸道合胞病毒(RSV)和人偏肺病毒(hMPV)的潜在的 VLP 组合候选疫苗。阿斯利康的这一收购行为，旨在获取 Icosavax 在蛋白质设计方面的专有技术，以及其在病毒样颗粒科学和开发方面的专业知识与能力，从而支持 IVX - A12 和其他用于治疗高负担呼吸道疾病的差异化 VLP 疫苗的开发，强势入局呼吸道疫苗市场。分析指出，呼吸道疾病的高发性和严重性是制药企业加大投入的重要原因。以呼吸道合胞病毒为例，它是一种传染性极强的季节性呼吸道病毒，5 岁以下儿童和老年人是易感人群，且目前没有针对性特效药。据相关数据显示，RSV 感染在全球范围内广泛传播，每年导致大量儿童和老年人患病，严重时可引发肺炎等危及生命的疾病。随着全球人口老龄化的加剧，以及人们对健康重视程度的提高，对呼吸道疫苗的需求愈发迫切。从市场前景来看，呼吸道疫苗市场潜力巨大。全球已上市的几款 RSV 疫苗在市场上取得了不俗的成绩。例如，葛兰素史克的Arexvy、辉瑞的 Abrysvo 在 2023 年 5 月上市后，销售额远超预期。有数据显示，RSV 药物全球整体市场规模(包括治疗药物及预防药物、疫苗)，预计将从 2020 年的 18 亿美元增长至 2030 年的 128 亿美元，年均复合增长率达到 21.4%。如此诱人的市场前景，吸引着越来越多的制药企业投身其中。目前，全球在研的 RSV 疫苗管线覆盖了多种技术路线，包括重组亚单位、mRNA、病毒载体、减毒活疫苗等。除了赛诺菲和阿斯利康，默沙东、强生、第一三共等跨国药企也在 RSV 领域积极布局。在国内，虽然大多数国产 RSV 疫苗仍处于临床前阶段，但已有超过 10 家疫苗企业参与研发，如艾棣维欣、沃森生物、智飞生物等。制药企业对呼吸道疫苗市场的投入不断加大，无论是赛诺菲收购 Vicebio，还是阿斯利康收购 Icosavax，都反映出该市场的巨大吸引力和发展潜力。随着各大药企的持续投入与研发，未来有望出现更多有效的呼吸道疫苗，为全球公共卫生事业带来新的曙光，更好地预防和控制呼吸道疾病的传播。识别微信二维码，添加生物制品圈小编，符合条件者即可加入生物制品微信群！请注明：姓名+研究方向！版权声明本公众号所有转载文章系出于传递更多信息之目的，且明确注明来源和作者，不希望被转载的媒体或个人可与我们联系(cbplib@163.com)，我们将立即进行删除处理。所有文章仅代表作者观不本站。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2554171521","isCrawlerRequest":true}